De Caprio L, De Rosa M L, Di Palma A, Lirato C, Caccese P, Sestito M, Lastoria S, Cicatiello A M, Rengo F
Cattedra di Geriatria, II Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli, Italy.
Cardiovasc Drugs Ther. 1994 Oct;8(5):735-40. doi: 10.1007/BF00877120.
Of 17 patients with mild to moderate essential hypertension, 8 showed echocardiographic evidence of left ventricular hypertrophy. Cardiac and renal function evaluated by glomerular filtration rate (GFR) were studied in all patients before and after 20 weeks of quinapril treatment. Systolic pressure decreased from 174.7 +/- 16.7 to 131.7 +/- 7.7 mmHg (p < .0001) and diastolic pressure decreased from 101.8 +/- 9.8 to 80 +/- 4.3 mmHg (p < .0001). Left ventricular mass index decreased in the eight patients with left ventricular hypertrophy (p < .01). Basal values of GFR were lower than normal in 41% of all patients; GFR increased significantly after 20 weeks of treatment (from 96.5 +/- 32.3 to 108.6 +/- 31.12 ml/min, p < .01); it decreased in only one patient. Patients reported few adverse effects to quinapril, and no important clinical laboratory abnormality was observed. Quinapril not only lowered arterial pressure, but it had a distinct effect on regression of left ventricular hypertrophy and favorable effects on renal function.
在17例轻至中度原发性高血压患者中,8例有超声心动图显示的左心室肥厚证据。在所有患者中,于喹那普利治疗20周前后,研究了通过肾小球滤过率(GFR)评估的心脏和肾功能。收缩压从174.7±16.7降至131.7±7.7 mmHg(p<.0001),舒张压从101.8±9.8降至80±4.3 mmHg(p<.0001)。8例左心室肥厚患者的左心室质量指数下降(p<.01)。41%的所有患者的GFR基础值低于正常;治疗20周后GFR显著增加(从96.5±32.3升至108.6±31.12 ml/min,p<.01);仅1例患者GFR下降。患者报告对喹那普利的不良反应很少,且未观察到重要的临床实验室异常。喹那普利不仅降低动脉压,而且对左心室肥厚的消退有明显作用,并对肾功能有有利影响。